Liquidia to pay $175M UTHR after settlement agreement
Liquidia (LQDA) and United Therapeutics (UTHR) settled all litigation, with LQDA agreeing to pay $175M within 30 days and $145.4M by 2027. LQDA will also pay $60.3M to resolve antitrust litigation. The companies terminated their promotional agreement for Treprostinil Injection. LQDA expects to fund payments from YUTREPIA sales and cash on hand, with Q3 2026 YUTREPIA sales at $222.7M and total cash at $396.1M.
How this was made
The 30-second read
Why it matters
The settlement resolves legal uncertainty but imposes a sizable cash outflow on Liquidia while providing a cash boost to United Therapeutics.
Market read
The settlement is a material corporate event for both firms, likely influencing short‑term price action.
What to watch
Potential future litigation costs and the impact of terminating the promotional agreement for Treprostinil Injection.
Background
Liquidia and United Therapeutics resolved pending antitrust litigation over Treprostinil Injection, with Liquidia paying a $175M settlement and terminating promotional activities.
Ticker impact
Liquidia agreed to pay United Therapeutics $175M settlement, plus additional installments, creating a near‑term cash outflow.
likely pressure as the market prices in the cash outflow
The settlement amount is sizable relative to Liquidia's cash ($396.1M) and will be funded from sales, reducing cash reserves.
United Therapeutics will receive a $175M net payment from Liquidia under the settlement, improving its cash position.
likely support as the market prices in the cash receipt
The payment adds significant cash without dilution, enhancing financial flexibility.
Market effects
Biotech settlement may prompt scrutiny of other antitrust disputes in the pulmonary‑arterial‑hypertension space.
Limited to U.S. biotech stocks; no broader regional effect.
Modest; primarily affects the two companies involved.
Counterpoint
The settlement could be seen as a catalyst for Liquidia to refocus on pipeline growth, mitigating long‑term risk.
Key entities
- CompanyLiquidia
Biotech firm developing inhaled therapies, ticker LQDA.
- CompanyUnited Therapeutics
Pharmaceutical company focused on pulmonary‑arterial‑hypertension, ticker UTHR.
